Publications by authors named "Francisco Gutierrez Henares"
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury.
Spinal Cord
August 2024
Article Synopsis
- Double-blind, randomized, placebo-controlled phase IIA trial tested the safety and pain relief efficacy of NFX-88 in chronic spinal cord injury (SCI) patients.
- A total of 61 adults with varying levels of SCI participated, receiving either a placebo or one of three NFX-88 doses alongside pregabalin.
- Results showed no severe side effects and indicated that the 2.1g/day dose of NFX-88 provided the most significant reduction in neuropathic pain, suggesting its potential for future trials.
Background: Recently we reported the design and evaluation of floating semi-implantable devices that receive power from and bidirectionally communicate with an external system using coupling by volume conduction. The approach, of which the semi-implantable devices are proof-of-concept prototypes, may overcome some limitations presented by existing neuroprostheses, especially those related to implant size and deployment, as the implants avoid bulky components and can be developed as threadlike devices. Here, it is reported the first-in-human acute demonstration of these devices for electromyography (EMG) sensing and electrical stimulation.
View Article and Find Full Text PDFThe COVID-19 pandemic represents an unprecedented global challenge in this century. COVID-19 is a viral respiratory infection, yet the clinical characteristics of this infection differ in spinal cord injury patients from those observed in the general population. Cough and asthenia are the most frequent symptoms in this population.
View Article and Find Full Text PDFStudy Design: Cohort study of patients with spinal cord injury (SCI).
Objectives: To describe the clinical and analytical features of a coronavirus disease 2019 (Covid-19) infected cohort with SCI to enable accurate diagnosis and to outline prevention measures.
Setting: This study was conducted at the National Hospital for Paraplegics (Toledo, Spain).